August 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results ~1 min.Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....
August 1, 2025Eli Lilly and Company Completes Acquisition of Verve Therapeutics, Advancing One-Time Treatments for High Cardiovascular Risk ~1 min.Eli Lilly and Company has announced the successful completion of its acquisition of Verve Therapeutics, a move that will help advance innovative one-time treatments for individuals with high cardiovascular risk. This strategic decision showcases the company's commitment to revolutionizing the healthcare industry and improving patient outcomes. Investors are eagerly watching as Eli Lilly continues ...
July 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan ~1 min.According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....
March 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation ~2 min.Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....
March 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results ~2 min.Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....
March 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry ~1 min.Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....
March 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry ~2 min.Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....
March 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry? ~2 min.Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....
March 14, 2025Eli Lilly and Company Reports Promising Results in Hair Regrowth Study ~1 min.Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....
February 28, 2025Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding 50 billion ~1 min.Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....
February 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development ~1 min.Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....
March 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments ~1 min.Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....
December 29, 2024Bristol Myers Squibb: Promising Results from Phase 3 Psoriatic Arthritis Trials ~1 min.Bristol Myers Squibb (BMY) recently announced positive topline results from its Phase 3 trials evaluating Sotyktu deucravacitinib in adults with psoriatic arthritis....
December 26, 2024Positive Results from Psoriatic Arthritis Trials Boost Bristol-Myers Squibb Stock ~1 min.Bristol-Myers Squibb Company (BMY), a leading pharmaceutical company, has recently announced positive topline results from two pivotal Phase 3 trials evaluating its drug Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials have shown promising outcomes, with the drug meeting key endpoints and demonstrating effectiveness in treating the condition. Psoriatic arthritis is a chronic ...
January 5, 2025Regeneron Pharmaceuticals: A Strong Performer with Promising Financials ~2 min.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been a steady performer in the biopharmaceutical industry, delivering a decent return of 89% for investors over the last five years....
